Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes

키워드

참고문헌 (47)

1. Gadiparthi C, "NAFLD epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States", J Clin Transl Hepatol, 8, pp.215~221 (2020)
2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
3. Murag Soumya, "Recent Epidemiology of Nonalcoholic Fatty Liver Disease", Gut and Liver, 15(2), pp.206~216 (2021), 거트앤리버 소화기연관학회협의회[DOI]
4. Chun HS, "Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 21, pp.358~369 (2023)
5. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
6. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
7. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]
8. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
9. Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
10. Lee H, "Metabolic dysfunctionassociated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
11. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness : the Rotterdam Study", Hepatology, 75, pp.419~429 (2022)
12. Huang Shang-Chin, "Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 15(3), pp.451~458 (2021), 거트앤리버 소화기연관학회협의회[DOI]
13. Ginès P, "Population screening for liver fibrosis : toward early diagnosis and intervention for chronic liver diseases", Hepatology, 75, pp.219~228 (2022)
14. Gwyneth Soon, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective", Clinical and Molecular Hepatology, 27(1), pp.44~57 (2021), 대한간학회[DOI]
15. Sheka AC, "Nonalcoholic steatohepatitis : a review", JAMA, 323, pp.1175~1183 (2020)
16. Han E, "Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk", Am J Gastroenterol, 115, pp.584~595 (2020)
17. Tamaki N, "Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease", J Gastroenterol Hepatol, 36, pp.2960~2966 (2021)
18. Wijarnpreecha Karn, "Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Clinical and Molecular Hepatology, 27(2), pp.221~235 (2021), 대한간학회[DOI]
19. Han Eugene, "Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 16(5), pp.786~797 (2022), 거트앤리버 소화기연관학회협의회[DOI]
20. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
21. McPherson S, "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)
22. 서미혜, "2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 28(1), pp.40~45 (2019), 대한비만학회[DOI]
23. 허규연, "2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association", Diabetes and Metabolism Journal, 45(4), pp.461~481 (2021), 대한당뇨병학회[DOI]
24. Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
25. 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
26. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
27. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
28. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
29. Angulo P, "Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis", Hepatology, 30, pp.1356~1362 (1999)
30. Bugianesi E, "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease : sites and mechanisms", Diabetologia, 48, pp.634~642 (2005)
31. El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
32. Younossi ZM, "Nonalcoholic fatty liver disease in patients with type 2 diabetes", Clin Gastroenterol Hepatol, 2, pp.262~265 (2004)
33. Sohn W, "Liver fibrosis in asians with metabolic dysfunction-associated fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.e1135~e1148 (2022)
34. Chen X, "Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality", J Hepatol, 75, pp.987~989 (2021)
35. Sookoian S, "Systematic review with meta-analysis : the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease", Aliment Pharmacol Ther, 47, pp.16~25 (2018)
36. Young S, "Prevalence and profile of nonalcoholic fatty liver disease in lean adults : systematic review and meta-analysis", Hepatol Commun, 4, pp.953~972 (2020)
37. Golabi P, "Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality", Clin Diabetes, 37, pp.65~72 (2019)
38. Yoshitaka H, "Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study", Medicine(Baltimore), 96, pp.e6712~ (2017)
39. Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
40. Younes R, "Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach", Gut, 71, pp.382~390 (2022)
41. Udompap P, "Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis", J Viral Hepat, 27, pp.437~448 (2020)
42. Aykut UE, "A comparison of FibroMeterTM NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease", Scand J Gastroenterol, 49, pp.1343~1348 (2014)
43. European Association for the Study of the Liver (EASL), "EASL-EASDEASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
44. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
45. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
46. Vilar-Gomez E, "Non-invasive assessment of non-alcoholic fatty liver disease : clinical prediction rules and blood-based biomarkers", J Hepatol, 68, pp.305~315 (2018)
47. Tae Seop Lim, "Is liver biopsy still useful in the era of non-invasive tests?", Clinical and Molecular Hepatology, 26(3), pp.302~304 (2020), 대한간학회

관련 논문AI추천